XHKG2251
Market cap206mUSD
Dec 23, Last price
12.10HKD
1D
0.00%
1Q
7.65%
IPO
-80.42%
Name
Beijing Airdoc Technology Co Ltd
Chart & Performance
P/E
—
P/S
7.38
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
204m
+79.46%
Net income
-133m
L-29.21%
CFO
23m
P
Profile
Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions and consumer healthcare providers in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-based software as a medical device for auxiliary diagnosis of diabetic retinopathy; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; and Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia, retinal detachment, glaucoma detection, cataracts detection, ICVD/ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial, hypertension retinopathy, and anemia. The company also provides health risk assessment solutions to detect risk indicators, such as various lesions and diseases, hyperthyroidism, graves ophthalmopathy, retinal vein occlusion, dementia, Parkinson's disease, atrial fibrillation, and arteriosclerosis in a range of healthcare environments, including health checkup centers, community clinics, insurance companies, optometry centers, and pharmacies. In addition, it offers hardware devices, including fundus cameras. The company was incorporated in 2015 and is headquartered in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 203,964 79.46% | 113,657 -1.32% | 115,181 141.61% | ||
Cost of revenue | 390,103 | 363,478 | 258,858 | ||
Unusual Expense (Income) | |||||
NOPBT | (186,139) | (249,821) | (143,677) | ||
NOPBT Margin | |||||
Operating Taxes | (205) | 4,493 | (5,533) | ||
Tax Rate | |||||
NOPAT | (185,934) | (254,314) | (138,144) | ||
Net income | (132,533) -29.21% | (187,233) 36.67% | (136,994) 72.05% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (10,442) | 2,320 | 1,635,267 | ||
BB yield | 0.87% | -0.16% | -60.59% | ||
| Debt | |||||
Debt current | 8,622 | 4,085 | 4,775 | ||
Long-term debt | 10,126 | 11,941 | 11,615 | ||
Deferred revenue | 4,200 | ||||
Other long-term liabilities | |||||
Net debt | (1,071,552) | (1,272,543) | (1,771,865) | ||
| Cash flow | |||||
Cash from operating activities | 23,371 | (380,443) | (112,093) | ||
CAPEX | (15,348) | (12,110) | (28,013) | ||
Cash from investing activities | (385,141) | (154,427) | (22,006) | ||
Cash from financing activities | (18,531) | (17,143) | 1,553,008 | ||
FCF | (37,647) | (443,808) | (155,173) | ||
| Balance | |||||
Cash | 1,143,243 | 1,412,984 | 1,784,648 | ||
Long term investments | (52,943) | (124,415) | 3,607 | ||
Excess cash | 1,080,102 | 1,282,886 | 1,782,496 | ||
Stockholders' equity | (357,125) | (156,603) | (7,979) | ||
Invested Capital | 1,928,483 | 1,828,588 | 1,830,930 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 103,505 | 103,002 | 80,932 | ||
Price | 11.60 -18.08% | 14.16 -57.54% | 33.35 | ||
Market cap | 1,200,655 -17.68% | 1,458,508 -45.96% | 2,699,082 | ||
EV | 146,504 | 191,202 | 927,217 | ||
EBITDA | (154,187) | (227,156) | (128,179) | ||
EV/EBITDA | |||||
Interest | 545 | 439 | 298 | ||
Interest/NOPBT | |||||